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BACKGROUND AND PURPOSE
3-Iodothyroacetic acid (TA1) is an end product of thyroid hormone metabolism. So far, it is not known if TA1 is present in
mouse brain and if it has any pharmacological effects.
EXPERIMENTAL APPROACH
TA1 levels in mouse brain were measured by HPLC coupled to mass spectrometry. After i.c.v. administration of exogenous TA1
(0.4, 1.32 and 4 μg·kg−1) to mice, memory acquisition-retention (passive avoidance paradigm with a light-dark box), pain
threshold to thermal stimulus (51.5°C; hot plate test) and plasma glucose (glucorefractometer) were evaluated. Similar assays
were performed in mice pretreated with s.c. injections of the histamine H1 receptor antagonist pyrilamine (10 mg·kg−1) or the
H2 receptor antagonist zolantidine (5 mg·kg−1). TA1 (1.32 and 4 μg·kg−1) was also given i.c.v. to mice lacking histidine
decarboxylase (HDC−/−) and the corresponding WT strain.
KEY RESULTS
TA1 was found in the brain of CD1 but not of HDC mice. Exogenous TA1 induced amnesia (at 0.4 μg·kg−1), stimulation of
learning (1.32 and 4 μg·kg−1), hyperalgesia (0.4, 1.32 and 4 μg·kg−1) and hyperglycaemia (1.32 and 4 μg·kg−1). All these
effects were modulated by pyrilamine and zolantidine. In HDC−/− mice, TA1 (1.32 and 4 μg·kg−1) did not increase plasma
glucose or induce hyperalgesia.
CONCLUSIONS AND IMPLICATIONS
Behavioural and metabolic effects of TA1 disclosed interactions between the thyroid and histaminergic systems.
Abbreviations
T3, tri-iodothyronine; TA1, 3-iodothyroacetic acid; TA1M, 3-iodothyronamine; TRIAC, tri-iodothyroacetic acid
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Introduction
The main pathways of tri-iodothyronine (T3) metabolism are
deiodination of the aromatic rings, decarboxylation or con-
jugation of the alanine chain, producing the corresponding
amines and esters, and transamination or oxidative deamina-
tion yielding acetic or propionic acid derivatives. The indi-
vidual steps of this complex metabolism require cell-specific
enzyme expression and can occur in different combinations,
generating a plethora of compounds bearing amino acidic,
amine and acidic moieties, with different degrees of
iodination.
While decarboxylation was classically believed to follow
deamination, it has recently been observed that thyron-
amines, lacking the carboxyl group and retaining the amine
group, are endogenous compounds and at least some of
them, in particular 3-iodothyronamine (T1AM), should be
regarded as chemical messengers (Scanlan et al., 2004; Saba
et al., 2010). T1AM has been detected in plasma of mammals
(Hoefig et al., 2011; Galli et al., 2012) and its levels increases
in pathological conditions including diabetes (Galli et al.,
2012). Acidic and amine derivatives are likely to differ in
terms of their pharmacodynamic properties. For instance,
while tri-iodothyroacetic acid (TRIAC) is an endogenous
antagonist at thyroid hormone receptors, thyronamines exert
rapid effects activating G-coupled membrane receptors
(Zucchi et al., 2006) and possibly interfering with membrane
transporters or mitochondrial proteins (Cumero et al.,
2012).
TRIAC is not the only acid metabolite of T3, as
3-iodothyroacetic (TA1) and thyroacetic acids (TA0) may
be produced by subsequent deiodination of TRIAC or by
oxidative deamination of T1AM and thyronamine (T0AM)
respectively. In the presence of deiodinases, TA0 can also be
produced. TA1 was recognized as the main oxidative metabo-
lite of T1AM (Wood et al., 2009; Saba et al., 2010; Agretti
et al., 2011), while TA0 was identified in human urine as the
final end product of thyroid hormone metabolism (Pittman
et al., 1972). In turn, TA1 can be transformed into T0A, in
cells expressing deiodinase activity.
We recently described some pharmacological effects of
low doses of T1AM, including stimulation of memory acqui-
sition and retention, increase of plasma glucose and reduc-
tion of pain threshold in mice. These effects occurred within
15 min after injection and were prevented in animals pre-
treated with clorgyline, an inhibitor of MAO activity (see
Alexander et al., 2013a). Moreover, clorgyline pretreatment
also increased the systemic bioavailability of T1AM given
i.c.v. (Manni et al., 2012). These findings suggested that gen-
eration of TA1 by deamination might contribute, at least in
part, to the acute effects of T1AM in vivo and showed that
oxidative deamination had a marked effect on T1AM phar-
macokinetics Overall, it can be hypothesized that T1AM, TA1,
and possibly TA0, should be considered as part of the large
family of thyroid hormone metabolites with potential bio-
logical activity.
Here, we have investigated whether endogenous TA1
could be found in mouse brain We have also evaluated poten-
tial signalling activity of exogenous TA1 in the CNS, by
assessing its effects on memory, pain threshold and plasma
glucose. The mechanism of action of TA1 was explored by
using histamine receptor antagonists (see Alexander et al.,
2013b) and by examining its effects in mice lacking histidine
decarboxylase (HDC−/−) and the corresponding WT mice.
Methods
Animals
All animal care and experimental procedures complied with
the National Institutes of Health Guide for the Care and Use
of Laboratory Animals (NIH Publications no. 80-23, revised
1996) and were approved by the Animal Care Committee of
the Department of Pharmacology, University of Florence, in
compliance with the European Convention for the Protection
of Vertebrate Animals used for Experimental and Other Sci-
entific Purposes (ETS no. 123) and the European Communi-
ties Council Directive of 24 November 1986 (86/609/EEC). All
efforts were made to minimize the number of animals used
and their suffering. Studies involving animals are reported in
accordance with the ARRIVE guidelines for reporting experi-
ments involving animals (Kilkenny et al., 2010; McGrath
et al., 2010). A total of 200 animals were used in the experi-
ments described here.
Male mice (CD1 strain; 20–30 g) from Harlan-Nossan
(Italy) were used. Animals were kept at 23 ± 1°C with a 12 h
light–dark cycle (light on at 07:00 h) and were fed a standard
laboratory diet with water ad libitum. Five mice were housed
per cage. Mice lacking histidine decarboxylase (HDC−/−) and
the corresponding WT strain (HDC+/+) on a 129/Sv back-
ground (18–22 g) were a kind gift from Dr Ohtsu, Japan
(Ohtsu et al., 2001). These animals were housed, four to six to
a cage, in standard transparent laboratory cages. Cages were
placed in the experimental room, 24 h before tests to allow
adaptation.
Detection of the HDC gene. The genotypes of the knockout
mice used with respect to the HDC gene were confirmed at
birth, by amplifying the DNA prepared from tail biopsies by
PCR, as described by Anaclet et al. (2009).
Detection of endogenous TA1 and T1AM
in brain
Four mice from each of the CD1, HDC+/+ and HDC−/− strains
(20–30 g) were killed by cervical dislocation. The brains were
isolated and quickly frozen at −80°C. TA1 and T1AM were
then assayed by HPLC coupled to tandem mass spectrometry,
as described previously (Saba et al., 2010), with the only dif-
ference that tissue was homogenized with ultrasound,
extracted with acetonitrile and then washed with hexane to
remove lipids
I.c.v. injection procedures
I.c.v. injection was performed under light ether anaesthesia
according to the method described by Haley and McCormick
(1957) with minor modifications. The depth of anaesthesia
was checked by monitoring respiratory rate (which was
reduced within 2 min) and testing the lack of pain response
to gentle pressure on the hind paws. The head of the anaes-
thetized mouse was grasped firmly and the needle of a 10 μL
microsyringe (Hamilton Bonaduz, Bonaduz, Switzerland) was
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inserted perpendicularly 2 mm through the skull into the
brain. Ten microliters of solution were then slowly injected
(in 20 s) into a lateral ventricle. The injection site was 1 mm
to the left from the midpoint on a line drawn through to the
anterior base of the ears. Immediately after needle removal,
the animal remained quiet for approximately 1 min and then
resumed its normal activity. To ascertain that solutions were
administered exactly into the cerebral ventricle, some mice
were injected with 10 μL of 1:10 India ink and their brains
were examined macroscopically after sectioning. 95% of the
i.c.v. injections were found to be correctly delivered.
The passive avoidance paradigm: the
light–dark box
The test was performed according to the step-through
method described by Jarvik and Kopp (1967). The experimen-
tal apparatus consisted of a two-compartment acrylic box
with a brightly lit compartment connected to a dark com-
partment by a guillotine door. The dark chamber was con-
structed with a pitfall floor. When entering this chamber in
the training session, mice receive a non-painful ‘punishment’
consisting of a fall (from 40 cm) into a cold water bath (10°C).
Because mice prefer dark to the light, they would usually
enter the dark compartment within 5 s. Mice not entering the
dark compartment within 60 s during the training session
were excluded from the experiment. The test was then
repeated 1 and 24 h after the training session. Each pharma-
cological treatment was performed before the training
session. In particular, mice received an i.c.v. injection of
10 μL of vehicle (Veh; 0.5% DMSO) or of TA1 (0.4, 1.32 and
4 μg·kg−1; n = 20 for each treatment) and, after 15 min, the
training session was performed.
In other sets of experiments, mice were pretreated with
i.p. scopolamine (0.3 mg·kg−1) or saline; with the histamine
H1 receptor antagonist pyrilamine (10 mg·kg−1, s.c.) or the
histamine H2 receptor antagonist zolantidine (5 mg·kg−1; s.c.)
or saline. 15 min later, they all were injected i.c.v. with Veh or
TA1. In all cases, the training session was performed 15 min
after injecting TA1, by placing mice on an illuminated plat-
form (60 W, 840 lux) and allowing them to enter the dark
compartment. The extent of ‘punishment’ memory was
expressed as the time (s) spent in the light portion during the
training and the retention sessions. Retention sessions were
performed 1 and 24 h after the training session. In the 1 and
24 h tests, each animal was placed on the platform and the
time taken to enter the dark compartment (latency) was
measured up to a maximum of 300 s.
Nociceptive thresholds to thermal stimulus
using the hot plate test
Mice received i.c.v. TA1 (0.4, 1.32 and 4 μg·kg−1) or Veh. (n =
20 for each group) and, 15 min later, they were placed on the
hot plate device (51.5 ± 1°C). The time taken to elicit a
flinching or jumping response (latency) was measured. The
cut-off time was set at 45 s to minimize skin damage. In other
sets of experiments, mice received a s.c. injection of pyril-
amine or zolantidine or saline or Veh. and after 15 min, TA1
was injected i.c.v. (0.4, 1.32 and 4 μg·kg−1). Mice were then
placed on the hot plate, 15 min after injection of TA1.
Nociceptive thresholds were evaluated in HDC−/− mice
and HDC+/+ mice, using the same procedures. Both strains of
mice were injected i.c.v. with Veh or TA1 (1.32 and 4 μg·kg−1;
n = 10 for each group of animals) and placed on the hot plate
15 min after TA1 injection.
Measurement of plasma glucose. Blood was collected from the
tail veins of mice, which had been starved for 4 h, 15 min
after i.c.v. injection of Veh or TA1 (0.4, 1.32 and 4 μg·kg–1,
n = 10 mice for each treatment). Glucose concentrations in
plasma were measured by a glucorefractometer, 15 min after
TA1 injection.
Using the same procedures, plasma glucose was measured
in mice pretreated with s.c. pyrilamine (10 mg·kg−1) or zolan-
tidine (5 mg·kg−1) or saline, 15 min before receiving i.c.v.
injection of TA1 (0.4, 1.32 or 4 μg·kg−1) or Veh (n = 10 for each
group). Plasma glucose was also measured in HDC−/− and
HDC+/+ 15 min following i.c.v. injection of Veh. or TA1 (1.32
or 4 μg·kg−1; n = 10 for each group).
Data analysis
Data are expressed as mean ± SEM of independent experi-
ments. Statistical analysis was performed by one-way ANOVA,
followed by Student–Newman–Keuls multiple comparison
post hoc test. When the experimental setting included only
two groups, unpaired t-test was used. The threshold of statis-
tical significance was set at P < 0.05. Data analysis was per-
formed by GraphPad Prism 5.0 statistical program (GraphPad
Software, San Diego, CA, USA).
Materials
TA1 was kindly provided by Dr Thomas Scanlan (Portland,
OR, USA) and was dissolved in 0.5% DMSO (Veh). Pyrilamine,
scopolamine and zolantidine were supplied by Sigma–
Aldrich, St. Louis, MO.
Results
Endogenous TA1 in the brain of CD1
euthyroid mice
The brains of CD1 mice were analysed for TA1 and T1AM by
HPLC coupled to mass spectrometry. Both T1AM and its
oxidative derivative, TA1, were found in concentrations of
48.6 ± 17.7 and 0.8 ± 0.2 pmol·g−1 of tissue, corresponding to
17.3 ± 6.2 and 0.30 ± 0.06 μg·kg−1 (n = 3) respectively. So, the
concentration of TA1 amounted to about 1.6% of that of
T1AM.
TA1 modifies learning, reduces pain threshold
and increases plasma glycaemia in CD1 mice
TA1, i.c.v. injected, at a dose close to its physiological levels
(0.4 μg·kg−1) produced amnesia in 1 and 24 h retention ses-
sions. On the contrary, at the doses of 1.32 and 4 μg·kg−1,
mice remained in the light portion of the box for a signifi-
cantly longer time in the 1 h retention session. Interestingly,
and differently from what occurred with T1AM (Manni et al.,
BJP C Musilli et al.
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2013), memory consolidation was not observed in the 24 h
retention session (Figure 1A).
In addition, 15 min after TA1 (0.4, 1.32 and 4 μg·kg−1)
injection, mice showed increased sensitivity (hyperalgesia) to
thermal stimulus of the hot plate (Figure 1B), and at the doses
of 1.32 and 4 μg·kg−1, plasma glucose was higher than control
values (Figure 1C).
Pretreatment with histamine receptor
antagonists prevents stimulation of memory,
hyperalgesia and increase of plasma glucose
TA1 was given i.c.v. to mice pretreated s.c. with saline or
pyrilamine (10 mg·kg−1), or zolantidine (5 mg·kg−1), antago-
nists of histamine H1 and H2 receptors respectively. As shown
in Figure 2A–C, pretreatment with the histamine receptor
antagonists per se did not modify memory acquisition, noci-
ceptive threshold or plasma glucose , but it markedly affected
the behavioural responses induced by TA1.
Pyrilamine pretreatment abolished the pro-learning effect
of 1.32 and 4 μg·kg−1 TA1, while the amnesic effect of
0.4 μg·kg−1 TA1 was maintained (Figure 3A). In mice pre-
treated with zolantidine, TA1, induced amnesia at all the
doses studied (Figure 3A).
Pretreatment with pyrilamine or zolantidine also affected
the hyperalgesic and the hyperglycaemic effect of TA1. In
particular, after either the H1 or H2 receptor antagonists,
hyperalgesia was induced only by the dose of 4 μg·kg−1
(Figure 2B) and plasma glucose did not rise at any of the doses
injected (Figure 2C). Taken together, these results suggested
that stimulation of memory, hyperalgesia and increase of
plasma glucose might have a common mechanism involving
the histaminergic system.
TA1, at the dose stimulating learning, was
also anti-amnesic
Memory acquisition and retention is a complex behaviour
controlled by an organized network of integrated signalling
including the muscarinic receptors. Because of this, scopola-
mine injection in rodents is often used to provide an experi-
mental model of amnesia and we tested the effects of TA1 on
such a model. In mice pretreated i.p. with scopolamine, at a
dose (0.3 mg·kg−1) which produced amnesia (Rush, 1988)
without inducing analgesia or sedative effects, injection of
1.32, but not 4 μg·kg−1, TA1 completely reversed the amnesia,
giving consolidation in the 1 h and also in the 24 h retention
session (Figure 3).
T1AM and TA1 in the brain of HDC+/+and
HDC−/− mice
The rate-limiting step in the biosynthesis of histamine is
catalysed by HDC. Although there are inhibitors of HDC
enzymic activity, genetic silencing of the HDC gene repre-
sents a strategy to obtain a mouse lacking histamine. Because
of this, HDC−/− mice could provide a suitable model to assess
the participation of the histaminergic system in the effects of
TA1. Interestingly, the WT (HDC+/+) mice exhibited signifi-
cantly lower brain levels of T1AM (0.22 ± 0.03 pmol·g−1 of
tissue; n = 4, P < 0.001) than found in CD1 mice (about 48
pmol·g−1 of tissue, see above) and the levels of TA1 were below
the limit of detection. In HDC−/− mice,.neither T1AM nor TA1
could be detected in brain tissue.
T1A effects in HDC−/− mice
During the training for the passive avoidance paradigm, only
a very few HDC+/+ or HDC−/− animals (1/15) entered the dark
side. This pattern of behaviour did not permit the effects
of TA1 on this task to be evaluated. However, both HDC+/+
A
B
C
Figure 1
TA1 modifies learning, reduces nociceptive threshold and increases
plasma glucose in mice. Mice (n = 20 for each groups of animals)
were injected i.c.v. with TA1 (0.4, 1.32 or 4 μg·kg−1 or with Veh and,
after 15 min, were assessed by the passive avoidance paradigm (A) or
their nociceptive threshold measured by the the hot plate test (B).
**P < 0.01, ***P < 0.001 versus Veh. Plasma glucose was also meas-
ured 15 min after TA1 injection, in blood collected from the tail veins
of 4 h starved mice (n = 10 for r each groups of animals). Results are
expressed as means ± SEM; *P < 0.05 versus Veh.
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and HDC−/− mice were responders in the hot plate test. In
HDC+/+ mice, the i.c.v. injection of TA1 (1.32 and 4 μg·kg−1)
produced hyperalgesia (Figure 4A) and raised plasma glucose
(Figure 4B). On the contrary, in HDC−/− mice, neither a hyper-
algesia nor increased plasma glucose was observed following
TA1 injection (Figure 4C and 4D)
Discussion
We here provide, for the first time, evidence that endogenous
TA1 was found in the brain of CD1 mice, representing 1.6%
of its putative precursor T1AM. In these animals, exogenous
TA1, injected i.c.v., produced rapid (within 15 min) effects
including modification of memory, of nociceptive threshold
and of plasma glucose. All these effects were modulated by
histamine H1 and H2 receptor antagonists. Furthermore, TA1
failed to raise plasma glucose and to induce hyperalgesia
when injected in mice lacking HDC, indicating that these
effects of TA1 (1.32 and 4 μg·kg−1) were mediated by hista-
mine release.
TA1 has been identified as the main oxidative metabolite
of T1AM in cardiac (Saba et al., 2010) and thyroid cells
(Agretti et al., 2011). Moreover, TA1 was recovered in mouse
A
B C
Figure 2
The effects of histamine H1 and H2 receptor antagonists on TA1-induced modification of learning, pain threshold and plasma glucose in mice. Mice
(n = 20 for each groups of animals) were pretreated s.c. with a single injection of pyrilamine (10 mg·kg−1) or zolantidine [5 mg·kg−1, 15 min before
the i.c.v. injection of T1A (0.4, 1.32 and 4 μg·kg−1) or Veh.]. 15 min after TA1 or Veh injection, mice were assessed by the passive avoidance
paradigm (A), or nociceptive thresholds determined by the hot plate test (B). Plasma glucose was also measured 15 min after TA1 (0.4, 1.32 and
4 μg·kg−1) i.c.v. injection in the blood collected from the tail veins of 4 h starved mice (n = 10 for each treatment) (C). Results are expressed as
means ± SEM. *P < 0.05, **P < 0.01,***P < 0.001 versus Veh.
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serum following i.p. administration of T1AM (Hackenmueller
and Scanlan, 2012), supporting the concept that T1AM and
TA1 are endogenous derivatives of the thyroid hormone and
that the latter can be produced from the former. Before the
present data, the evidence for TA1 in mouse brain was
lacking. In this respect, our data demonstrated the presence
of TA1 and of T1AM, the amine from which it derives, in CD1
mice and also provide an estimate of their reciprocal levels.
Furthermore, our data indicating very low levels of T1AM or
TA1 in mice of the 129/Sv strain (HDC-/- or HDC+/+), suggest
there is a considerable strain-related difference in thyroid
hormone metabolism.
One way to demonstrate the function of endogenous
compounds is to observe the effects produced by their phar-
macological administration in rodents. Here, we have dem-
onstrated that i.c.v. injection of TA1, at doses close to its
endogenous levels, modified behaviour, including memory
acquisition and reduced nociceptive thresholds and raised
plasma glucose. In particular, the effect of TA1 on memory
was dose-dependent, ,with the lowest dose at 0.4 μg·kg−1
exerting amnesic effects but being pro-learning at 1.32 and
4 μg·kg−1 without retention in the 24 h post-training session.
Overall, these results show a difference between TA1 and
T1AM, as the latter when used in almost equimolar doses, to
those used in this paper for TA1, never produced amnesia
(Manni et al., 2012). Given that that very little is known of the
pharmacokinetics of TA1 and of the impact, if any, of exog-
enous TA1 on endogenous levels of T1AM, one can hypoth-
esise that the acid induces the release amnesic or pro-learning
mediators depending on its levels at cell target(s), or that
T1AM effects are not entirely mediated by TA1.
However, at all the doses tested, TA1, like T1AM, induced
hyperalgesia and hyperglycaemia. All these findings indi-
cated TA1, like T1AM, had the potential to behave as a novel
mediator, and encouraged elucidation of its mechanism of
action.
We first observed that the effects of TA1 (stimulation of
memory, reduction of pain threshold and increase of plasma
glycaemia) were not modulated by amiloride (40 μmol·kg−1
i.p.; data not shown), a non-selective antagonist of the acid-
sensitive channels involved in memory and pain (Chu et al.,
2011). Modification of memory, increase of plasma glucose
and reduction of pain threshold were reported following i.c.v.
injection of histamine and of selective histamine receptor
agonists in rodents (Nishibori et al., 1987; Ishibory et al.,
1990; Galeotti et al., 2004). Because of this, we explored the
hypothesis that histamine might be involved in the effects of
TA1. Our data showed that in the presence of H1 or H2 recep-
tor antagonists, the pro-learning, the hyperalgesic and the
hyperglycaemic effects induced by TA1 were all markedly
changed, suggesting the involvement of histamine in all
these effects of TA1.
It is well known that the effects of histamine and related
compounds on memory depend on the brain region where
they are injected, on the type of test used and on the receptor
subtype involved (Köhler et al., 2011), complicating the inter-
pretation of results. For instance, drugs modulating the his-
tamine H3 receptor reverse scopolamine-induced amnesia
in different experimental settings (Köhler et al., 2011).
We found, here, that T1A (1.32 but not 4 μg·kg−1) reversed
scopolamine-induced amnesia, producing a long-lasting
memory consolidation, which persisted in the 24 h retention
session. This latter result potentially suggests H3 receptors as
a target for TA1, a hypothesis, which, however, needs appro-
priate experiments to be verified. In any case, this anti-
amnesic effect adds to our knowledge of the effects of TA1 on
memory and may further support the involvement of hista-
mine release in the pharmacological effects of TA1.
Figure 3
TA1 reversed scopolamine-induced amnesia. TA1, 1.32 and 4 μg·kg−1 (n = 10 for each dose) or Veh were injected i.c.v. in mice (n = 20 for each
groups of animals) pretreated i.p. with scopolamine (0.3 mg·kg−1, n = 30) or saline. Mice were then assessed by the passive avoidance paradigm.
Results are expressed as means ± SEM. §P < 0.05 and §§§P < 0.001 versus Veh. + scopolamine, ***P < 0.001 versus Veh.
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In our experimentals, it is not possible to locate the sites
where histamine release could have occurred as i.c.v. injec-
tion of TA1 ensures that it was distributed throughout the
CNS. However, we observed that pretreatment of mice with
pyrilamine abolished the pro-learning effect of 1.32 and
4 μg·kg−1 TA1, whereas the amnesic effect of 0.4 μg·kg−1 TA1
was maintained. In contrast, with zolantidine pretreatment,
TA1 was amnesic at all the doses tested. As we used a single
antagonist in our experiments , we cannot draw conclusions
on the receptor subtype involved in these effects. On the
other hand, treatment with more than one antagonist could
produce ambiguous results. With all the limitations of the
settings, a major involvement of histamine H2 and H1 recep-
tors in the pro-learning and amnesic effects, respectively, of
TA1 can be postulated.
Pyrilamine and zolantidine pretreatment also affected
hyperalgesia and hyperglycaemia induced by TA1. In particu-
lar, in the presence of H1 or H2 receptor blockade, the hyper-
algesic and hyperglycaemic effects of TA1 were evident only
at the highest dose of 4 μg·kg−1, a finding, which again cannot
exclude the involvement of the H3 receptor subtype (Hough
and Rice, 2011).
Evidence indicating that the hyperalgesic and hypergly-
caemic effects of TA1 were linked to histamine release were
obtained in the HDC−/− mice. In this animal model, TA1
injection (1.32 and 4 μg·kg−1) failed to increase plasma
glucose and to induce hyperalgesia to the thermal stimulus.
Instead, in HDC+/+ mice both hyperalgesia and hyperglycae-
mia were evident with the latter effect being greater than in
CD1 mice. Unfortunately, we could not verify the effect of
TA1 on learning behaviour in HDC+/+ and HDC−/− mice
because, as described in the Results, both these strains failed
in the passive avoidance paradigm. The reason for such a
failure is not known at present, but it may be related to the
absence of TA1 in their brains. In fact, our results showed that
in both HDC+/+ and HDC−/− brain levels of TA1 were undetec-
table, indicating that there is a marked strain-dependent dif-
ference in endogenous levels of this metabolite of the thyroid
hormone. However, taken together, our results strengthened
the interaction between histamine and metabolites of the
thyroid hormone.
Based on the neurological signs and symptoms associated
with thyroid disorders in adults, the thyroid hormone plays
fundamental roles in the nervous system, well after the well-
known effects on development are complete. As an animal
matures, subcellular accumulation of thyroid hormone in
neurons changes to a characteristically adult pattern of
concentration suggesting non-genomic, neurotransmitter-
like mechanisms of action (Dratman and Gordon, 1996).
In line with this hypothesis, our findings confirm that an
A B
C D
Figure 4
T1A failed to induce hyperglycaemia and to raise plasma glucose when injected i.c.v. in HDC−/− mice. TA1 (1.32 and 4 μg·kg−1), or Veh, were
injected i.c.v. in HDC+/+ and HDC−/− mice (n = 10 for each group of animals). After 15 min, nociceptive thresholds to a thermal stimulus and plasma
glucose were evaluated in HDC+/+ (A and B) and in HDC−/− mice (C and D). Results are presented as the means ± SEM. *P < 0.05 versus Veh;
**P < 0.01 versus Veh.
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end-product of T3 metabolism, TA1, may be considered a
novel endogenous mediator, active in memory and nocicep-
tive sensitivity, two physiological processes known to be
modified in conditions of thyroid dysfunction (Guieu et al.,
1993; Rivas and Naranjo, 2007). As TA1 is generated by oxi-
dative deamination (by constitutive MAO activity) and/or
deiodination of amine derivatives of thyroid hormone
metabolites, the intracellular bioavailability of T3 potentially
represents the limiting step in TA1 formation. Furthermore,
endogenous levels were TA1 are strain-specific and would be
expected to be modified under conditions of overexpression
or pharmacological inhibition of the enzymes involved in
its biosynthesis (Pino et al., 1997; Metszaros et al., 1999;
Masini-Repiso et al., 2004; Petrovic et al., 2005). The conse-
quences of each of these circumstances on the pharmacologi-
cal effects of TA1 are not known and represent a potential
topic of research interest.
Thyromimetic compounds devoid of genomic activity
have been extensively studied for their potential therapeutic
usefulness in ameliorating hyperlipidaemia and the associ-
ated cardiovascular risk (Tancevski et al., 2011). We here
present TA1 as a novel endogenous thyromimetic whose
(non-genomic) behavioural and metabolic effects reveal the
existence of a signalling pathway integrating thyroid and the
histaminergic system. This interaction might have clinical
relevance in explaining the occurrence of some symptoms
associated with thyroid dysfunctions (Hiramanek, 2004).
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